Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China; Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, 201203, China.
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China; Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, 201203, China.
J Ethnopharmacol. 2020 Nov 15;262:113214. doi: 10.1016/j.jep.2020.113214. Epub 2020 Jul 29.
Our clinical practice demonstrated that Jueyin granules (JYG) benefit patients with mild to moderate psoriasis vulgaris without apparent adverse effects. JYG have been shown to inhibit epidermal proliferation in an imiquimod (IMQ)-induced psoriasis-like mouse model, as well as keratinocyte proliferation. Moreover, JYG causes no acute or chronic toxicity in animal models. However, its related molecular mechanism has still not been elucidated.
To assess the mechanism of JYG against psoriasis.
This study combined network pharmacology analysis with experiments to investigate the mechanism of JYG against psoriasis. First, the molecular docking technology was used to construct the network of medicinal materials-core active plant ingredients-core targets and identify possible drug targets. Next, high-performance liquid chromatography (HPLC) was used for quality control of JYG. Finally, a mice model of psoriasis was used to further verify the effects of JYG.
(1) Molecular docking analysis of network pharmacology revealed that the therapeutic effects of JYG on psoriasis might be achieved through Vitamin D Receptor (VDR) effects. (2) The concentrations of chlorogenic acid and paeoniflorin were determined using HPLC to establish quality control of JYG. (3) JYG ameliorated pathological characteristics that included in vivo reductions in erythema, scale, and infiltration scores of back and ear lesions in IMQ-induced psoriasis-like mice. Moreover, a reduced number of PCNA-positive and Ki67-positive cells were observed in the epidermis of JYG-treated lesions. JYG also reduced inflammation (interleukin (IL)-17, IL-23) in the peripheral blood of IMQ-induced psoriasis-like mice. As expected, JYG was found to upregulate VDR expression and downregulate p-STAT3 expression in the IMQ group, which may contribute to its mechanism against psoriasis.
Overall, this study clarifies the mechanism of JYG against psoriasis and provides evidence to support its clinical use.
我们的临床实践表明，银屑颗粒（JYG）有益于轻度至中度寻常型银屑病患者，且无明显不良反应。JYG 已被证明可在咪喹莫特（IMQ）诱导的银屑病样小鼠模型中抑制表皮增殖以及角质形成细胞增殖。此外，JYG 在动物模型中无急性或慢性毒性。然而，其相关的分子机制尚未阐明。
评估 JYG 治疗银屑病的机制。
本研究结合网络药理学分析和实验，研究 JYG 治疗银屑病的机制。首先，采用分子对接技术构建药材-核心活性植物成分-核心靶点网络，并鉴定可能的药物靶点。其次，采用高效液相色谱法（HPLC）对 JYG 进行质量控制。最后，采用银屑病小鼠模型进一步验证 JYG 的作用。
（1）网络药理学的分子对接分析表明，JYG 治疗银屑病的疗效可能通过维生素 D 受体（VDR）作用实现。（2）采用 HPLC 测定绿原酸和芍药苷的浓度，建立 JYG 的质量控制方法。（3）JYG 改善了银屑病样小鼠的病理特征，包括背部和耳部病变的红斑、鳞屑和浸润评分的体内降低。此外，JYG 处理的病变表皮中 PCNA 阳性和 Ki67 阳性细胞数量减少。JYG 还降低了 IMQ 诱导的银屑病样小鼠外周血中的炎症（白细胞介素（IL）-17、IL-23）。正如预期的那样，JYG 被发现可上调 IMQ 组中的 VDR 表达并下调 p-STAT3 表达，这可能有助于其治疗银屑病的机制。
总体而言，本研究阐明了 JYG 治疗银屑病的机制，并为其临床应用提供了证据支持。
